Polyinosinic-polycytidylic acid (Poly(I:C)) is a double-stranded RNA (dsRNA) and a TLR3 agonist. Polyinosinic-polycytidylic acid induces natural immunity in mammals.

METHODS: Cervical cancer cells HeLa, SiHa, C33A and lung cancer cells A549 were treated with polyinosinic-polycytidylic acid (0.1-1 μg/mL) for 24 h, and cell death was detected using PI Staining.
RESULTS: Polyinosinic-polycytidylic acid effectively induced tumor cell death in a dose-dependent pattern. [1]
METHODS: Rat astrocytes were pretreated with polyinosinic-polycytidylic acid (10-20 μg/mL) for 12 h, and then exposed to oxygen-glucose deprivation (OGD) for 12 h. The morphology of the cells was examined by microscopy.
RESULTS: OGD induced significant cellular damage, and the cells appeared to be healthier in the group pretreated with polyinosinic-polycytidylic acid.Polyinosinic-polycytidylic acid exerted a certain degree of protective effect against OGD-induced damage in cultured astrocytes. [2]

METHODS: To investigate the neuroprotective effects in an acute ischemia model, Polyinosinic-polycytidylic acid (0.3 mg/kg) was administered as a single intramuscular injection to Kun-Ming strain mice, and a model of arterial occlusion (MCAO) was constructed 2 h later.
RESULTS: Administration of polyinosinic-polycytidylic acid significantly attenuated neurological deficits in the ischemic striatum and cortex, reduced infarct volume, and suppressed the elevation of TNFα and IL-6 levels. [2]
METHODS: To test the antitumor activity in vivo, Polyinosinic-polycytidylic acid (1-100 μg/mouse) was intraperitoneally injected into a mouse model of metastatic tumors C57BL/6J induced by cutaneous melanoma B16-F10.
RESULTS: Lung tumor growth stopped after a single dose of Polyinosinic-polycytidylic acid. Polyinosinic-polycytidylic acid has potential antitumor activity in an established mouse model of lung metastasis. [3]